Specify a stock or a cryptocurrency in the search bar to get a summary
Cyclo Therapeutics Inc
CYTHCyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida. Address: 6714 NW 16th Street, Gainesville, FL, United States, 32653
Analytics
WallStreet Target Price
0.95 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CYTH
Dividend Analytics CYTH
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CYTH
Stock Valuation CYTH
Financials CYTH
Results | 2019 | Dynamics |